|  |  | |||||||||
 Dr. Robertson's Practice | |||||||||||
    | |||||||||||
 | |||||||||||
 Dr M. Robertson: Home Page: Article |  | ||||||||||
| | |||||||||||||||||||||||||
 | ||||||||||||||||||||||||||
 | ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
 | ||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||
 | ||||||||||||||||||||||||||
| ||
|
Parkinson Disease
What Is Parkinson Disease?
Parkinson disease (PD) belongs to a group of conditions called motor system disorders, which are the result of the loss of dopamine-producing brain cells. The four primary symptoms of PD are tremor, or trembling in hands, arms, legs, jaw and face; rigidity, or stiffness of the limbs and trunk; bradykinesia or slowness of movement; and postural instability, or impaired balance and coordination. As these symptoms become more pronounced, patients may have difficulty walking, talking or completing other simple tasks. PD usually affects people older than age 50. Early symptoms of PD are subtle and occur gradually. In some people, the disease progresses more quickly than in others. As the disease progresses, the shaking, or tremor, which affects the majority of PD patients, may begin to interfere with daily activities. Other symptoms may include depression and other emotional changes; difficulty in swallowing, chewing, and speaking; urinary problems or constipation; skin problems; and sleep disruptions. There are currently no blood or laboratory tests that have been proven to help in diagnosing sporadic PD. Therefore the diagnosis is based on medical history and a neurological examination. The disease can be difficult to diagnose accurately. Doctors may sometimes request brain scans or laboratory tests in order to rule out other diseases. Is There Any Treatment? At present, there is no cure for PD, but a variety of medications provide dramatic relief from the symptoms. Usually, patients are given levodopa combined with carbidopa. Carbidopa delays the conversion of levodopa into dopamine until it reaches the brain. Nerve cells can use levodopa to make dopamine and replenish the brain's dwindling supply. Although levodopa helps at least three-quarters of parkinsonian cases, not all symptoms respond equally to the drug. Bradykinesia and rigidity respond best, while tremor may be only marginally reduced. Problems with balance and other symptoms may not be alleviated at all. Anticholinergics may help control tremor and rigidity. Other drugs, such as bromocriptine, pramipexole and ropinirole, mimic the role of dopamine in the brain, causing the neurons to react as they would to dopamine. An antiviral drug, amantadine, also appears to reduce symptoms. In May 2006, the U.S. Food and Drug Administration approved rasagiline to be used along with levodopa for patients with advanced PD or as a single-drug treatment for early PD. In some cases, surgery may be appropriate if the disease doesn't respond to drugs. A therapy called deep brain stimulation (DBS) has now been approved by the FDA. In DBS, electrodes are implanted into the brain and connected to a small electrical device called a pulse generator that can be externally programmed. DBS can reduce the need for levodopa and related drugs, which in turn decreases the involuntary movements called dyskinesias that are a common side effect of levodopa. It also helps to alleviate fluctuations of symptoms and to reduce tremors, slowness of movements and gait problems. DBS requires careful programming of the stimulator device in order to work correctly. What Is the Prognosis? PD is both chronic, meaning it persists over a long period of time, and progressive, meaning its symptoms grow worse over time. Although some people become severely disabled, others experience only minor motor disruptions. Tremor is the major symptom for some patients, while for others tremor is only a minor complaint and other symptoms are more troublesome. No one can predict which symptoms will affect an individual patient, and the intensity of the symptoms also varies from person to person. What Research Is Being Done? The National Institute of Neurological Disorders and Stroke, a part of the National Institutes of Health, conducts PD research in laboratories and also supports additional research through grants to major medical institutions across the country. Current research programs funded by the NINDS are using animal models to study how the disease progresses and to develop new drug therapies. Scientists looking for the cause of PD continue to search for possible environmental factors, such as toxins, that may trigger the disorder, and study genetic factors to determine how defective genes play a role. Other scientists are working to develop new protective drugs that can delay, prevent or reverse the disease. Additional Resources
American Parkinson Disease Association
National Parkinson Foundation
Parkinson Alliance
Michael J. Fox Foundation for Parkinson's Research
Parkinson's Action Network (PAN)
Parkinson's Disease Foundation (PDF)
Parkinson's Institute
Parkinson's Resource Organization
WE MOVE (Worldwide Education & Awareness for Movement Disorders)
Bachmann-Strauss Dystonia & Parkinson Foundation Source: National Institute of Neurological Disorders and Stroke, National Institutes of Health Updated: May 15, 2007 Related Articles
| |
 |
|
 | |
| |
|
 Top | |||
| |||
© Medem, Inc. All Rights Reserved
|
